Clinical Trial Update: Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of the meningococcal group B vaccine Bexsero to prevent gonorrhea (gonococcal infection).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• Bexsero (Meningococcal group B vaccine (4CMenB))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gonococcal Infection | Phase 2 | Status: ACTIVE_NOT_RECRUITING